Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Core Insights - Intellia Therapeutics reported significant progress in 2025, including positive Phase 1/2 clinical data for lonvo-z and nex-z, and plans for a potential launch of lonvo-z for Hereditary Angioedema (HAE) in 2027 [2][4] Business Updates - The company is preparing for a pivotal year ahead with topline Phase 3 data and a planned Biologics License Application (BLA) submission for lonvo-z, which aims to transform HAE treatment [2][4] - Intellia is focused on resuming momentum with nex-z by completing patient enrollment in the MAGNITUDE-2 trial and resolving the clinical hold on the MAGNITUDE trial [2][4] Product Development - Lonvo-z is an investigational CRISPR-based therapy targeting the KLKB1 gene to reduce HAE attacks through a one-time treatment [3] - Nex-z is designed to inactivate the TTR gene to halt and reverse transthyretin amyloidosis, with ongoing collaboration with Regeneron Pharmaceuticals [6] Clinical Trials - HAELO Phase 3 clinical data for lonvo-z is expected by mid-2026, with a BLA submission anticipated in the second half of 2026 and a U.S. launch planned for the first half of 2027 [4] - Enrollment for the MAGNITUDE-2 trial is expected to be completed in the second half of 2026, with ongoing FDA engagement to resolve the clinical hold on the MAGNITUDE trial [4][9] Financial Performance - As of December 31, 2025, the company had approximately $605 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2027 [4][9] - Collaboration revenue for Q4 2025 was $23 million, up from $12.9 million in Q4 2024, driven by a terminated collaboration agreement and increased cost reimbursements [9][15] - R&D expenses decreased to $88.7 million in Q4 2025 from $116.9 million in Q4 2024, while G&A expenses slightly increased to $33.1 million [9][15] Market Research - A blinded market research study indicated that 99% of HAE patients would be at least somewhat likely to take lonvo-z if prescribed, with 92% of healthcare providers indicating they would prescribe it [5]